Search

Your search keyword '"Widmark, Anders"' showing total 319 results
Start Over Author "Widmark, Anders" Publication Type Academic Journals
319 results on '"Widmark, Anders"'

1. Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging

Author

Grefve, Josefine, Söderkvist, Karin, Gunnlaugsson, Adalsteinn, Sandgren, Kristina, Jonsson, Joakim, Keeratijarut Lindberg, Angsana, Nilsson, Erik, Axelsson, Jan, Bergh, Anders, Zackrisson, Björn, Moreau, Mathieu, Thellenberg Karlsson, Camilla, Olsson, Lars.E., Widmark, Anders, Riklund, Katrine, Blomqvist, Lennart, Berg Loegager, Vibeke, Strandberg, Sara N., and Nyholm, Tufve

Published
2024
Full Text
View/download PDF

4. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Author

Parnis, Francis, Joshua, Anthony M., Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Gurney, Howard, Ferguson, Thomas, Van Bruwaene, Siska, Luyten, Daisy, Schatteman, Peter, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Seront, Emmanuel, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Pinczowski, Hélio, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Fizazi, Karim, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Eymard, Jean-Christophe, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Leibowitz-Amit, Raya, Mermershtain, Wilmosh, Rouvinov, Keren, Peer, Avivit, Kovel, Svetlana, Sella, Avishay, Lolkema, Martijn P., van den Eertwegh, Alfonsus J.M., Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Kim, Choung-Soo, Choi, Young-Deuk, Chung, Byung-Ha, Gafanov, Rustem A., Kopyltsov, Evgeniy, Usynin, Evgeny A., Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Estellés, David Lorente, Sarrió, Regina Gironés, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Ståhl, Olof, Chiang, Po-Hui, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Wu, Hsi-Chin, Lu, Yu-Chuan, Attard, Gerhardt, Khoo, Vincent, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Sieber, Paul R., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Flaig, Thomas W., Emamekhoo, Hamid, Pinski, Jacek K., Kalebasty, Arash Rezazadeh, Maly, Joseph J., Moon, Helen, Smith, Matthew R, Scher, Howard I, Lara, Primo N, Jr, Yu, Evan Y, George, Daniel J, Chi, Kim N, Danila, Daniel C, Mason, Gary E, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, and Lopez-Gitlitz, Angela

Published
2022
Full Text
View/download PDF

7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

Author

Fransson, Per, Nilsson, Per, Gunnlaugsson, Adalsteinn, Beckman, Lars, Tavelin, Björn, Norman, David, Thellenberg-Karlsson, Camilla, Hoyer, Morten, Lagerlund, Magnus, Kindblom, Jon, Ginman, Claes, Johansson, Bengt, Björnlinger, Kirsten, Seke, Mihajl, Agrup, Måns, Zackrisson, Björn, Kjellén, Elisabeth, Franzén, Lars, and Widmark, Anders

Published
2021
Full Text
View/download PDF

17. Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET.

Author

Sandgren, Kristina, Strandberg, Sara N., Jonsson, Joakim H., Grefve, Josefine, Lindberg, Angsana Keeratijarut, Nilsson, Erik, Bergh, Anders, Söderkvist, Karin, Karlsson, Camilla Thellenberg, Friedrich, Bengt, Widmark, Anders, Blomqvist, Lennart, Loegager, Vibeke Berg, Axelsson, Jan, Ögren, Mattias, Ögren, Margareta, Nyholm, Tufve, and Riklund, Katrine

Published
2023
Full Text
View/download PDF

18. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice

Author

Reza, Mariana, Ohlsson, Mattias, Kaboteh, Reza, Anand, Aseem, Franck-Lissbrant, Ingela, Damber, Jan-Erik, Widmark, Anders, Thellenberg-Karlsson, Camilla, Budäus, Lars, Steuber, Thomas, Eichenauer, Till, Wollmer, Per, Edenbrandt, Lars, Trägårdh, Elin, and Bjartell, Anders

Published
2016
Full Text
View/download PDF

21. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Author

Sartor, Oliver, Coleman, Robert, Nilsson, Sten, Heinrich, Daniel, Helle, Svein I, O'Sullivan, Joe M, Fosså, Sophie D, Chodacki, Aleš, Wiechno, Paweł, Logue, John, Widmark, Anders, Johannessen, Dag Clement, Hoskin, Peter, James, Nicholas D, Solberg, Arne, Syndikus, Isabel, Vogelzang, Nicholas J, O'Bryan-Tear, C Gillies, Shan, Minghua, Bruland, Øyvind S, and Parker, Christopher

Published
2014
Full Text
View/download PDF

23. Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328.

Author

Järemo, Helena, Semenas, Julius, Bergström, Sofia Halin, Lundholm, Marie, Thysell, Elin, Widmark, Anders, Crnalic, Sead, Ylitalo, Erik Bovinder, Bergh, Anders, Brattsand, Maria, and Wikström, Pernilla

Subjects
DISEASE progression, IN vitro studies, BONES, BLOOD vessels, MICRORNA, PROSTATE, PROTEOMICS, COMPARATIVE studies, BONE metastasis, BIOCHIPS, RESEARCH funding, TUMOR markers, PROSTATE tumors, EXTRACELLULAR vesicles
Abstract

Simple Summary: Bone metastatic prostate cancer is a lethal disease, and improved treatment strategies are urgently needed. MicroRNAs (miRNAs) are short non-coding RNAs with therapeutic possibilities in cancer. The current study compared levels of 1510 miRNAs in prostate cancer bone metastases with corresponding levels in the normal prostate and in localized prostate tumors, and found downregulation of a set of miRNAs during disease progression (miRNA-1, -23c, -143-3p, -143-5p, -145-3p, -205-5p, -221-3p, -222-3p and -4328). The downregulation of those miRNAs during the development of bone metastases may lead to a loss of inhibitory effects on prostate cancer cells. Functional studies confirmed the inhibiting effects of miRNA-23c and -4328 on prostate cancer cell growth in culture, while no clear effects of miRNA-23c were observed on tumor growth in mice. MicroRNAs (miRNAs) are aberrantly expressed in prostate cancer (PC), but comprehensive knowledge about their levels and function in metastatic PC is lacking. Here, we explored the differential expression of miRNA profiles during PC progression to bone metastasis, and further focused on the downregulation of miRNA-23c and -4328 and their impact on PC growth in experimental models. Using microarray screening, the levels of 1510 miRNAs were compared between bone metastases (n = 14), localized PC (n = 7) and benign prostate tissue (n = 7). Differentially expressed miRNAs (n = 4 increased and n = 75 decreased, p < 0.05) were identified, of which miRNA-1, -23c, -143-3p, -143-5p, -145-3p, -205-5p, -221-3p, -222-3p and -4328 showed consistent downregulation during disease progression (benign > localized PC > bone metastases). The downregulation of miRNA-23c and -4328 was confirmed by reverse transcription and quantitative polymerase chain reaction analysis of 67 metastasis, 12 localized PC and 12 benign prostate tissue samples. The stable overexpression of miRNA-23c and -4328 in the 22Rv1 and PC-3 cell lines resulted in reduced PC cell growth in vitro, and in the secretion of high levels of miRNA-23c (but not -4328) in extracellular vesicles. However, no tumor suppressive effects were observed from miRNA-23c overexpression in PC-3 cells subcutaneously grown in mice. In conclusion, bone metastases display a profound reduction of miRNA levels compared to localized PC and benign disease. The downregulation of those miRNAs, including miRNA-23c and -4328, may lead to a loss of tumor suppressive effects and provide biomarker and therapeutic possibilities that deserve to be further explored. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).

Author

Josefsson, Andreas, Jellvert, Åsa, Holmberg, Erik, Brasso, Klaus, Meidahl Petersen, Peter, Aaltomaa, Sirpa, Luukkaa, Marjaana, Verhagen, Paul, de Wit, Ronald, Ahlgren, Göran, Andrén, Ove, Castellanos, Enrique, Seke, Mihalj, Widmark, Anders, and Damber, Jan-Erik

Subjects
ANTIANDROGENS, COMBINATION drug therapy, HORMONE therapy, CONFIDENCE intervals, ANTINEOPLASTIC agents, CANCER relapse, DISEASE relapse, TREATMENT effectiveness, RANDOMIZED controlled trials, DOCETAXEL, DESCRIPTIVE statistics, RESEARCH funding, PROSTATE-specific antigen, PROGRESSION-free survival, DATA analysis software, PROSTATE tumors, PROPORTIONAL hazards models
Abstract

Historically, endocrine therapy was used in a range of scenarios in patients with rising PSA, both as a treatment for locally advanced non-metastatic prostate cancer and PSA recurrence following curative intended therapy. In the present study the objective was to investigate if chemotherapy added to endocrine therapy could improve progression-free survival (PFS). Patients with hormone-naïve, non-metastatic prostate cancer and rising prostate-specific antigen (PSA), enrolled from Sweden, Denmark, the Netherlands, and Finland, were randomized to long-term bicalutamide (150 mg daily) or plus docetaxel (75 mg/m2, q3w, 8–10 cycles) without prednisone, after stratification for the site, prior local therapy or not, and PSA doubling time. The primary endpoint was 5-year PFS analyzed with a stratified Cox proportional hazards regression model on intention to treat basis. Between 2009 and 2018, a total of 348 patients were randomized; 315 patients had PSA relapse after radical treatment, 33 patients had no prior local therapy. Median follow-up was 4.9 years (IQR 4.0–5.1). Adding docetaxel improved PFS (HR 0.68, 95% CI 0.50–0.93; p = 0.015). Docetaxel showed an advantage for patients with PSA relapse after prior local therapy (HR 0.67, 95% CI 0.49–0.94; p = 0.019). One event of neutropenic infection/fever occurred in 27% of the patients receiving docetaxel. Limitations were slow recruitment, lack of enrolling patients without radical local treatment, and too short follow-up for evaluation of overall survival in patients with PSA relapse. Docetaxel improved PFS in patients starting bicalutamide due to PSA relapse after local therapy or localized disease without local therapy. Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to endocrine therapies may be justified if longer follow-up will show increased metastatic-free survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy.

Author

Wikström, Pernilla, Bergström, Sofia Halin, Josefsson, Andreas, Semenas, Julius, Nordstrand, Annika, Thysell, Elin, Crnalic, Sead, Widmark, Anders, Karlsson, Camilla Thellenberg, and Bergh, Anders

Subjects
PROSTATE tumors treatment, EPITHELIAL cell tumors, STATISTICS, ANTIANDROGENS, ACADEMIC medical centers, SMOOTH muscle, IMMUNOHISTOCHEMISTRY, MANN Whitney U Test, CANCER patients, BONE metastasis, GENE expression profiling, SURVIVAL analysis (Biometry), CHI-squared test, CELL proliferation, TUMOR markers, DATA analysis, DATA analysis software, PROSTATE tumors, PROPORTIONAL hazards models
Abstract

Simple Summary: Metastatic prostate cancer is a lethal disease and metastasis-specific treatments need to be developed. Mechanisms driving metastases and primary tumor growth could be different, but this is largely unexplored. We previously discovered that bone metastases can be separated into transcriptomic-based subtypes, showing different responses to standard androgen-deprivation therapy for metastatic prostate cancer. One subtype, named MetB, is particularly aggressive and has the worst prognosis. Here, we describe similarities and differences between primary tumors and their metastases, and specifically examine if the development of specific subtype of bone metastases can be predicted by analyzing the primary tumor. Results show that many aspects of prostate cancer bone metastases morphology are related to those in the primary tumor, while others are not. Importantly, men with primary tumors with high cell proliferation and low cellular PSA expression tend to develop metastases enriched for the MetB subtype, have poor prognosis, and need complementary treatment to standard hormone treatment. Prostate cancer (PC) bone metastases can be divided into transcriptomic subtypes, by us termed MetA-C. The MetB subtype, constituting about 20% of the cases, is characterized by high cell cycle activity, low androgen receptor (AR) activity, and a limited response to standard androgen deprivation therapy (ADT). Complementary treatments should preferably be introduced early on if the risk of developing metastases of the MetB subtype is predicted to behigh. In this study, we therefore examined if the bone metastatic subtype and patient outcome after ADT could be predicted by immunohistochemical analysis of epithelial and stromal cell markers in primary tumor biopsies obtained at diagnosis (n = 98). In this advanced patient group, primary tumor International Society of Urological Pathology (ISUP) grade was not associated with outcome or metastasis subtype. In contrast, high tumor cell Ki67 labeling (proliferation) in combination with low tumor cell immunoreactivity for PSA, and a low fraction of AR positive stroma cells in the primary tumors were prognostic for poor survival after ADT. Accordingly, the same tissue markers were associated with developing metastases enriched for the aggressive MetB subtype. The development of the contrasting MetA subtype, showing the best response to ADT, could be predicted by the opposite staining pattern. We conclude that outcome after ADT and metastasis subtype can, at least to some extent, be predicted by analysis of primary tumor characteristics, such as tumor cell proliferation and PSA expression, and AR expression in stromal cells. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.

Author

Thysell, Elin, Köhn, Linda, Semenas, Julius, Järemo, Helena, Freyhult, Eva, Lundholm, Marie, Thellenberg Karlsson, Camilla, Damber, Jan-Erik, Widmark, Anders, Crnalic, Sead, Josefsson, Andreas, Welén, Karin, Nilsson, Rolf J. A., Bergh, Anders, and Wikström, Pernilla

Abstract

To improve treatment of metastatic prostate cancer, the biology of metastases needs to be understood. We recently described three subtypes of prostate cancer bone metastases (MetA-C), based on differential gene expression. The aim of this study was to verify the clinical relevance of these subtypes and to explore their biology and relations to genetic drivers. Freshly-frozen metastasis samples were obtained as hormone-naive (n = 17), short-term castrated (n = 21), or castration-resistant (n = 65) from a total of 67 patients. Previously published sequencing data from 573 metastasis samples were also analyzed. Through transcriptome profiling and sample classification based on a set of predefined MetA-C-differentiating genes, we found that most metastases were heterogeneous for the MetA-C subtypes. Overall, MetA was the most common subtype, while MetB was significantly enriched in castration-resistant samples and in liver metastases, and consistently associated with poor prognosis. By gene set enrichment analysis, the phenotype of MetA was described by high androgen response, protein secretion and adipogenesis, MetB by high cell cycle activity and DNA repair, and MetC by epithelial-to-mesenchymal transition and inflammation. The MetB subtype demonstrated single nucleotide variants of RB transcriptional corepressor 1 (RB1) and loss of 21 genes at chromosome 13, including RB1, but provided independent prognostic value to those genetic aberrations. In conclusion, a distinct set of gene transcripts can be used to classify prostate cancer metastases into the subtypes MetA-C. The MetA-C subtypes show diverse biology, organ tropism, and prognosis. The MetA-C classification may be used independently, or in combination with genetic markers, primarily to identify MetB patients in need of complementary therapy to conventional androgen receptor-targeting treatments. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Paediatric diagnostic reference levels for common radiological examinations using the European guidelines.

Author

Almén, Anja, Guðjónsdóttir, Jónína, Heimland, Nils, Højgaard, Britta, Waltenburg, Hanne, and Widmark, Anders

Subjects
PEDIATRICS, AGE groups, CLINICAL indications, ACQUISITION of data
Abstract

The purpose of this study was to explore the feasibility to determine regional diagnostic reference levels (RDRLs) for paediatric conventional and CT examinations using the European guidelines and to compare RDRLs derived from weight and age groups, respectively. Data were collected from 31 hospitals in 4 countries, for 7 examination types for a total of 2978 patients. RDRLs were derived for each weight and age group, respectively, when the total number of patients exceeded 15. It was possible to derive RDRLs for most, but not all, weight-based and age-based groups for the seven examinations. The result using weight-based and age-based groups differed substantially. The RDRLs were lower than or equal to the European and recently published national DRLs. It is feasible to derive RDRLs. However, a thorough review of the clinical indications and methodologies has to be performed previous to data collection. This study does not support the notion that DRLs derived using age and weight groups are exchangeable. Paediatric DRLs should be derived using weight-based groups with access to the actual weight of the patients. DRLs developed using weight differ markedly from those developed with the use of age. There is still a need to harmonize the method to derive solid DRLs for paediatric radiological examinations. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA): 684

Author

Sartor, Oliver, Heinrich, Daniel, Helle, Svein Inge, OʼSullivan, Joe M., Chodacki, Aleš, Demkow, Tomasz, Logue, John, Seke, Mihalj, Widmark, Anders, Johannessen, Dag Clement, Nilsson, Sten, Hoskin, Peter, Solberg, Arne, James, Nicholas D., Syndikus, Isabel, Vogelzang, Nicholas, OʼBryan-Tear, Charles Gillies, Garcia-Vargas, Jose, Shan, Minghua, and Parker, Chris

Published
2012

48. 493 - PROSTATE CANCER RISK CLASSIFICATION FROM MULTIPARAMETRIC MRI AND PET IMAGE DATA EVALUATED BY REGISTERED HISTOPATHOLOGY

Author

Nilsson, Mr Erik, Sandgren, Ms. Kristina, Strandberg, Sara, Jonsson, Joakim, Grefve, Ms. Josefine, Lindberg, Angsana Keeratijarut, Bergh, Anders, Söderström, Karin, Karlsson, Camilla Thellenberg, Friedrich, Bengt, Widmark, Anders, Blomqvist, Lennart, Løgager, Vibeke, Axelsson, Mr. Jan, Ögren, Mr. Mattias, Ögren, Ms. Margareta, Riklund, Katrine, and Nyholm, Tufve

Published
2022
Full Text
View/download PDF

49. 513 - IDENTIFICATION OF INTRA-PROSTATIC LESIONS USING PSMA, ACETATE-PET AND MPMRI

Author

Grefve, Ms Josefine, Sandgren, Ms Kristina, Strandberg, Sara, Jonsson, Joakim, Lindberg, Angsana Keeratijarut, Nilsson, Mr Erik, Bergh, Anders, Söderkvist, Karin, Karlsson, Camilla Thellenberg, Friedrich, Bengt, Widmark, Anders, Blomqvist, Lennart, Loegager, Vibeke, Axelsson, Jan, Ögren, Mattias, Ögren, Margareta, Nyholm, Tufve, and Riklund, Katrine

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results